Our study aims to investigate the predictive value of serum albumin and short-term mortality in patients with Acute Coronary Syndrome (ACS)
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Patients aged 18 years or older who were admitted to the emergency department or coronary care unit with a diagnosis of acute coronary syndrome (ACS) will be eligible for inclusion.
Exclusion Criteria:
1. Patients with a history of chronic liver disease, nephrotic syndrome, or other conditions known to affect serum albumin levels.
2. Patients receiving albumin infusions or other treatments that could potentially interfere with serum albumin levels.
3. Patients with incomplete medical records or missing laboratory data.
4. Patients who declined to participate in the study.
Primary outcome measure(s)
Value of Serum Albumin in Patients With Acute Coronary Syndrome — 12 week after the end of treatment low serum albumin is associated with increased adverse clinical outcomes and prognosis in cancer, heart failure, stroke, and stable coronary artery disease (CAD). Similarly, in patients with ACS, presence of hypoalbuminemia has been associated with increased severity of coronary lesions, no-reflow, increased in-hospital, and long-term mortality as well as development of heart failure
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.